Brought to you by 
Celgene pays $177.25mm up front for major OncoMed stem cell therapy deal
05 Oct 2021
Executive Summary
Celgene Corp. signed a major cancer stem cell (CSC) therapy deal with OncoMed Pharmaceuticals Inc. that could be worth over $3bn if all milestones are realized.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Celgene pays $177.25mm up front for major OncoMed stem cell therapy deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice